Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,706 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: SCHIZOPHRENIA Clear all
Completed Phase 3 Interventional

New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia

NCT00161018
View directory record Official record
Conditions
Schizophrenia
Interventions
Quetiapine, Risperidone, Fluphenazine
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 2, 2026, 7:59 AM EDT
Completed Not applicable Interventional

Treatment of Post Traumatic Stress Disorder in Patients With Other Mental Illnesses

NCT00053690
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Cognitive Behavior Treatment
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Claremont, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Sep 2, 2026, 7:59 AM EDT
Completed Phase 4 Interventional

Cognitive Skills Training Using Computer for Patients With Severe Mental Illness

NCT01036282
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Computerized Cognitive Skill Training, CRT and Social Cognition
Behavioral
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 2, 2026, 7:59 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia

NCT03781115
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone, Olanzapine, Placebo Comparator
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 2, 2026, 7:59 AM EDT
Completed Phase 1 Interventional

Comparative Bioavailability of Risperidone.

NCT05179525
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone ISM® 100 mg, Risperdal 4mg Tablet
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Garden Grove, California • Gaithersburg, Maryland • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 2, 2026, 7:59 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

NCT07145918
View directory record Official record
Conditions
Schizophrenia
Interventions
Emraclidine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Little Rock, Arkansas • Garden Grove, California • Glendale, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 2, 2026, 7:59 AM EDT
Completed Not applicable Interventional

Evaluating the Use of Peer Specialists to Deliver Cognitive Behavioral Social Skills Training

NCT03467243
View directory record Official record
Conditions
Serious Mental Illness
Interventions
Cognitive Behavioral Social Skills Training, Social Skills Training, Treatment as usual
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 2, 2026, 7:59 AM EDT
Recruiting Not applicable Interventional

Multiomic Diagnostics in Youth With Psychosis

NCT05457140
View directory record Official record
Conditions
Psychosis
Interventions
Genetic: Genomic sequencing and molecular diagnostic results, if any., Phage display ImmunoPrecipiation Sequencing (PhIP-Seq)
Genetic · Diagnostic Test
Lead sponsor
Rady Pediatric Genomics & Systems Medicine Institute
Other
Eligibility
7 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Sep 2, 2026, 7:59 AM EDT
Completed Phase 1 Interventional

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

NCT01774435
View directory record Official record
Conditions
Schizophrenia
Interventions
EN3342
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Sep 2, 2026, 7:59 AM EDT
Withdrawn No phase listed Observational

Sleep Quality, Cognitive Performance, and Computerized Cognitive Training

NCT06328140
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Psychosis
Interventions
Lurasidone, FDA Approved antidepressant treatment
Drug
Lead sponsor
George West Mental Health Foundation d/b/a Skyland Trail
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 2, 2026, 7:59 AM EDT
Completed Not applicable Interventional Results available

Therapeutic Efficacy of Transcranial Magnetic Stimulation in Schizophrenia

NCT01551979
View directory record Official record
Conditions
Schizophrenia
Interventions
Repetitive Transcranial Magnetic Stimulation
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Sep 2, 2026, 7:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study

NCT02421146
View directory record Official record
Conditions
Chronic Schizophrenia
Interventions
Transcranial direct current stimulation, Transcranial direct current stimulation - Sham
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Sep 2, 2026, 7:59 AM EDT
Not listed Phase 4 Interventional

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

NCT06093451
View directory record Official record
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions
Dexmedetomidine, Lorazepam 2 MG/ML
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 2, 2026, 7:59 AM EDT
Completed Phase 4 Interventional

Risperidone Augmentation in Patients With Schizophrenia

NCT00289861
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 2, 2026, 7:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Homeless Youth Study - Stepping Stone 2.0

NCT03776422
View directory record Official record
Conditions
Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)
Interventions
Mobile self-help intervention
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
16 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Sep 2, 2026, 7:59 AM EDT
Completed Phase 4 Interventional

Target Engagement and Response to Oxytocin

NCT03245437
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin nasal spray, Social Cognition Skills Training, Health Management, Placebo nasal spray
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 2, 2026, 7:59 AM EDT
Terminated Phase 2 Interventional Results available

Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1

NCT03507127
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Sep 2, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia

NCT04092686
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856 75mg, SEP-363856 100mg, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
18
States / cities
Rogers, Arkansas • Anaheim, California • Bellflower, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 2, 2026, 7:59 AM EDT
Completed Not applicable Interventional

Assessment and Treatment for Chronic Pain in Veterans With Serious Mental Illness

NCT04118283
View directory record Official record
Conditions
Chronic Pain, Schizophrenia, Psychotic Disorders, Bipolar Disorder, Affective Disorders, Psychotic
Interventions
Cognitive Behavioral Therapy for Chronic Pain, Health and Wellness
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 2, 2026, 7:59 AM EDT
Completed Phase 2 Interventional Results available

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01393600
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
NBI-98854, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Little Rock, Arkansas • National City, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 2, 2026, 7:59 AM EDT
Terminated No phase listed Observational

Role Functioning Changes NOS

NCT02505022
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Bipolar Disorder
Interventions
Pharmacotherapy, Behavioral treatment
Drug · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 26 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Sep 2, 2026, 7:59 AM EDT
Completed Phase 3 Interventional Results available

Pediatric Schizophrenia Efficacy and Safety Study

NCT01911429
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone 40 mg, Lurasidone 80 mg, Placebo 40 or 80 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
36
States / cities
Dothan, Alabama • Anaheim, California • Bakersfield, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 2, 2026, 7:59 AM EDT
Recruiting Not applicable Interventional

Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis

NCT04368039
View directory record Official record
Conditions
Psychosis, Schizophrenia, First-episode Psychosis
Interventions
Normobaric Oxygen, Placebo
Device
Lead sponsor
Nicholas Breitborde
Other
Eligibility
15 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 2, 2026, 7:59 AM EDT
Recruiting Phase 4 Interventional

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

NCT07213466
View directory record Official record
Conditions
Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
Interventions
Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination)
Behavioral · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 2, 2026, 7:59 AM EDT